Earnings Summary: Rigel Pharmaceuticals Q4
Benzinga Insights 8 months ago
Earnings
The Q4 earnings report for Rigel Pharmaceuticals (NASDAQ:RIGL) was released on Tuesday, March 3, 2026 at 04:01 PM.
Here's what investors need to know about the latest announcement.
Earnings
Rigel Pharmaceuticals missed estimated earnings by -10.4%, reporting an EPS of $1.12 versus an estimate of $1.25.
Revenue was up $12.21 million from the same period last year.
Earnings History Overview
During the previous quarter, the company beat on EPS by $0.61, leading to a 33.37% increase share price change the next day.
Here's a look at Rigel Pharmaceuticals's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 0.85 | 1.63 | 0.09 | 0.55 |
| EPS Actual | 1.46 | 3.28 | 0.63 | 0.80 |
| Revenue Estimate | 61.76M | 75.08M | 43.87M | 57.59M |
| Revenue Actual | 69.46M | 101.69M | 53.30M | 57.60M |
To track all earnings releases for Rigel Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.